Foresite Capital

Foresite Capital does not chase noise. Foresite Capital studies signal. In a market crowded with capital tourists, this firm moves like a specialist surgeon, precise, clinical, and focused on long arcs of value creation. Founded in 2011 by Jim Tananbaum, MD, the firm was engineered around a thesis that now feels obvious but once required conviction: biology plus big data will define the next era of healthcare. With more than $3.5B in AUM and offices spanning the San Francisco Bay Area, Los Angeles, and New York City, Foresite Capital has positioned itself as a structural force inside the modern startup ecosystem for life sciences.

Jim Tananbaum, MD did not arrive as a spreadsheet investor. He co-founded GelTex Pharmaceuticals and Theravance, then helped build Prospect Ventures. Operator first, allocator second. That sequence matters. Because underwriting drug discovery, genomics platforms, and precision medicine infrastructure demands fluency in clinical risk, regulatory friction, and capital intensity. Foresite Capital reflects that discipline. Fund IV closed at $668M. Fund V at $969M. Fund VI at $900M. The capital stack is built for duration, not optics.

The leadership bench reinforces the thesis. Michael Rome, PhD serves as Managing Director. Alisa Mall serves as Managing Director. Vikram Bajaj, PhD operates as Co-Founder and CEO of Foresite Labs and Managing Director at Foresite Capital, bridging incubation and institutional deployment. In 2024, Hyung Chun, MD and Cindy Xiong, PhD were promoted to Partner, deepening domain strength across therapeutics and platform biology. This is healthcare-only, data-science-driven investing with board-level engagement, not passive participation.

The portfolio maps the frontier. 10x Genomics. Relay Therapeutics. Element Biosciences. Lyell Immunopharma. Inscripta. Gemini Therapeutics. These are not incremental plays. They are infrastructure layers and therapeutic engines powering precision medicine. Across its first 4 funds, Foresite Capital has participated in more than 37 IPOs, a statistic that signals repeatable execution inside the public markets as much as private ones. In the broader startup ecosystem, that kind of graduation rate shifts perception from venture firm to category architect.

Then there is Foresite Labs, the internal build studio where AI, computation, and experimental biology are integrated from day 1. Company formation is not accidental here. Data architecture is embedded before scale. Scientific platforms are designed to compound across indications. In a healthcare startup ecosystem that often fragments between capital and company creation, Foresite runs them in parallel.

For founders, the filter is sharp: deep science, platform ambition, credible regulatory strategy, and the capacity to build through volatility. For operators and scientists, the opportunity set is real. Foresite-backed companies continue to scale across R&D, computational biology, clinical development, and technical infrastructure. If you are mapping where capital, biology, and AI intersect inside today’s startup ecosystem, Foresite Capital belongs on the short list.

Follow this firm. Study their founders. Track their plays.